Jobs
View more job listings or post a job
Applied Cells Research Associate
Applied Cells Application Scientist
Juvena Therapeutics Principal Data Scientist – Drug Discovery & Development
Juvena Therapeutics Senior Computational Biologist – Proteomics
Peak Bio Research Associate - Translation
Peak Bio Director, Antibody Drug Conjugate CMC
Peak Bio Cell/Tumor Biologist - Scientist
Peak Bio Research Associate - Molecular and Cell Biology
Peak Bio Senior Research Associate/Scientist - Protein Production
Peak Bio Analytical/Bioanalytical Scientist
Post a job

Symposium

[Free Online Symposium] Advances in Cancer Therapeutics


Speakers: Thorsten Melcher, RefleXion Medical; Erin Filbert, Apexigen; Pina Cardarelli, GPCR Therapeutics; Seema Kantak, Exelixis; Samuel Blackman, Day One Biopharmaceuticals; Holger Wesche, Harpoon Therapeutics Inc.; Mikayel Nazloyan, PricewaterhouseCoopers; James Trager, Nkarta Therapeutics; Kristin Bedard, Sutro Biopharma; Sarah Bodary, AbCellera; Steve Kelsey, Revolution Medicines; Tian Zhao, OncoNano
Organizers: Snow Ge, PhD; Toby Freedman, PhD; Wenfeng Xu, PhD; Donald McCarthy, PhD; Betty Chang, PhD; Joe Carlino, PhD; Peter Staehr, MD; Shichang Miao, PhD
Date: 2022-08-17- 08/18/2022
Time: 8:30-12:30 Pacific Time
Registration fee: 0
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2022-08-16  (it will close sooner if the seating cap is reached)

About the Topic

Note: This is an online meeting, The Zoom link will be sent to the registrants 1+ days before the event.


About the Speakers

  • James Trager, CSO, Nkarta Therapeutics
  • Kristin Bedard, VP Discovery, Sutro Biopharma
  • Pina Cardarelli, CSO, GPCR Therapeutics  
  • Seema Kantak, SVP, Head of Biologics & Biotherapeutics, Exelixis
  • Samuel Blackman, CMO, Day One Biopharmaceuticals
  • Erin Filbert, Director of IO, Apexigen
  • Steve Kelsey, President, Research and Development, Revolution Medicines
  • Thorsten Melcher, CBO, RefleXion Medical 
  • Mikayel Nazloyan, Partner, PricewaterhouseCoopers
  • Sarah Bodary, VP Portfolio Innovation and Partnering, AbCellera
  • Holger Wesche, CSO, Harpoon Therapeutics Inc.
  • Tian Zhao, VP R&D, OncoNano

 

August 17th Agenda

Time (PDT)

Time (EST)

Topic

Presenter

8:30-8:45am

11:30-11:45am

Welcome Remarks

 

8:45-9:20am

11:45-12:20pm

Biology-Guided External-Beam Radiotherapy for All Stages of Cancer

Thorsten Melcher, PhD, CBO, RefleXion Medical 

9:20-9:55am

12:20-12:55pm

APX601: a potent TNFR2 antagonist for reversing tumor-mediated immune suppression

Erin Filbert, PhD, Director of IO, Apexigen

9:55-10:30am

12:55-1:30pm

Targeting GPCRs: CXCR4 and ADRB2 for the Treatment of Cancer

Pina Cardarelli, PhD, CSO, GPCR Therapeutics 

10:30-10:45am

1:30-1:45pm

Break

--

10:45-11:20am

1:44-2:20pm

Anti-tissue factor ADC. XB002: A novel anti-tissue factor ADC for the treatment of solid tumors

Seema Kantak, PhD, SVP, Head of Biologics & Biotherapeutics, Exelixis

11:20-11:55am

2:20-2:55pm

Clinical Development of Tovorafenib, a pan-RAF Inhibitor, for Relapsed/Progressive Pediatric Low-Grade Glioma

Sam Blackman, MD, PhD, CMO, Day One Biopharmaceutical

11:55-12:30pm

2:55-3:30pm

Novel Approaches to Expand the Therapeutic Index of T cell Engagers

Holger Wesche, PhD, CSO, Harpoon Therapeutics Inc.

12:30-12:50pm

3:30-3:50pm

 

PANEL DISCUSSION

 

 

All speakers

 

 

August 18th Agenda

Time (PDT)

Time (EST)

Topic

Presenter

8:30-8:45am

11:30-11:45am

Welcome Remarks

 

8:45-9:20am

11:45-12:20pm

Financing Trends in Oncology

Mikayel Nazloyan, Partner, PricewaterhouseCoopers

9:20-9:55am

12:20-12:55pm

Progress in the development of CAR NK cell therapies for cancer

James Trager, PhD, CSO, Nkarta, Inc

9:55-10:30am

12:55-1:30pm

Complex Biologics for Cancer Treatment: ADCs and Beyond

Kristin Bedard, PhD, VP Discovery, Sutro Biopharma

10:30-10:45am

1:30-1:45pm

Break

--

10:45-11:20am

1:44-2:20pm

Business Development trends in the dynamic oncology market

Sarah Bodary, PhD, VP Portfolio Innovation and Partnering, AbCellera

11:20-11:55am

2:20-2:55pm

Targeting RAS-addicted cancers with tricomplex RAS(ON) inhibitors

Steve Kelsey, MD, President, Research and Development, Revolution Medicines

11:55-12:30pm

2:55-3:30pm

Tumor specific delivery of therapeutics using a clinically validated ultra pH-sensitive nanoparticle platform

Tian Zhao, Ph.D., VP R&D, OncoNano Medicine

12:30-12:50pm

3:30-3:50pm

 

PANEL DISCUSSION

 

 

All speakers

 

 


2022-10-21, [Free Online Workshop] MicroPhysiological Systems (MPS) such as "Organ-on-a-Chip" as a Tool For Drug Candidate Evaluation: Technologies, Applications and Regulatory Aspects
2022-11-02, [Free Online workshop] Bispecific Antibodies: Discovery, Engineering, Development and Regulatory Considerations
2022-11-14, [Free Online Symposium] Preclinical and Clinical Development of Cell-based Cancer Immunotherapies: Discovery, Translational PKPD, Safety, Biomarkers, Immunogenicity, CMC, Clinical Pharmacology & Clinical Trials (co-organized by AAPS)
2022-12-06, [Free Online Symposium] Gene Therapy: Discovery, Development and Regulatory Perspectives
┬ęPharmaceutical & BioScience Society, International; Last Modified: 9/26/2022; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
iPRECIO Programmable Pumps PK/PD models and the limitations of traditional dosing methods. Methods & benefits of implantable microinfusion pumps in both rats & mice.
iPRECIO Programmable Pumps Evaluate drug efficacy in animal models in a clinically relevant manner with a Programmable Refillable and implantable pump. 3Rs and group housed.
Submit a Text Ad